tiprankstipranks
Trending News
More News >

Ascletis Pharma Unveils Promising ASC47 Weight Loss Results

Ascletis Pharma Unveils Promising ASC47 Weight Loss Results

Ascletis Pharma, Inc. (HK:1672) has released an update.

Confident Investing Starts Here:

Ascletis Pharma Inc. revealed promising Phase I study results for its innovative weight loss drug, ASC47, showcasing significant fat reduction and muscle preservation compared to existing treatments. The study in Australia highlighted ASC47’s potential for once-monthly administration due to its 21-day half-life and impressive tolerance profile with minimal adverse effects. These findings position ASC47 as a compelling candidate in the obesity treatment market, with further studies underway.

For further insights into HK:1672 stock, check out TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1